The industry currently relies on petri dishes, flasks, and bioreactors designed for chemical or microbial systems, not complex mammalian cells.
It costs about $2B to bring a drug to market, and roughly 90% of candidates fail*. With ~24K drug programs run by ~2,300 companies, this “value destruction” is on the order of $2-4 trillion over their lifecycles (~$250B per year).
For too long, we have tried to engineer biology the way we engineer machines, by imposing control. But living systems don’t yield to command; they respond to context. They adapt, evolve, and self-organize. The companies that will define the next era of biomanufacturing will be those that learn to work with biology, not against it.
GPUs made AI programmable and scalable.
By incorporating hardware, software, and wetware in a cohesive platform, Bio-OS makes living systems programmable, scalable, and investable.
Bio-OS provides standardized, repeatable compute cores of biology; modular units that make cell behavior consistent, predictable, and scalable.
Standardization delivers acceleration:
Bio-OS makes living systems reproducible, programmable, and scalable while placing Ronawk at the forefront of setting standards others will have to follow.
Its operating rules are embedded, thereby turning biology into a programmable, scalable, and investable platform.
Manufactuing
Continuous cell production
Assembly
Controlled assembly of multiple cell types into tissues
Diagnostic
Multiple data points from a single sample rather than many
Engineering
Unparalleled control over cell phenotype